Fibrosis quística y el virus SARS-CoV-2: una revisión
DOI:
https://doi.org/10.31644/RMI.V4N5.2024.A11Palabras clave:
COVID-19, Fibrosis quística, Gen ACE, Gen TMPRSS2, Regulador de la conductancia transmembrana de la fibrosis quística (CFTR)Resumen
La fibrosis quística (FQ) es una enfermedad autosómica recesiva que afecta el transporte de iones, causando anormalidades en conductos y órganos secretores, tales como los tractos respiratorio y gastrointestinal. Debido a que la FQ está asociada con insuficiencia respiratoria y daño pulmonar, al inicio de la pandemia de COVID-19, se esperaba una mayor susceptibilidad en este grupo de pacientes. Sin embargo, diversos estudios mostraron tasas de infección más bajas en comparación con la población general. En esta revisión se describen los conceptos fundamentales de la FQ y el SARS-CoV-2 y se discuten los efectos beneficiosos y adversos observados en pacientes con FQ ante la COVID-19.
Descargas
Citas
Abolhasani FS, Moein M, Rezaie N, Sheikhimehrabadi P, Shafiei M, Afkhami H, Modaresi M (2024). Occurrence of COVID-19 in cystic fibrosis patients: a review. Front Microbiol. 15:1356926 https://doi.org/10.3389/fmicb.2024.1356926
Al Yazidi L., Al Maskari N. & Al Reesi M. (2021). Children with cystic fibrosis hospitalized with COVID-19: multicentre experience. J Paediatric Child Health, 57(5): 767-768. https://doi.org/10.1111/jpc.15495
Almughem F., Aldossary A., Tawfik E., Alomary M., Alharbi W., Alshahrani M. & Alshehri A. (2020). Cystic fibrosis: overview of the current development trends and innovative therapeutic strategies. Pharmaceutics, 12(7): 616. https://doi.org/0.3390/pharmaceutics12070616
Bai C., Zhong Q. & Gao GF. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. Feb;65(2):280-294. https://doi.org/10.1007/s11427-021-1964-4.
Bain R., Cosgriff R., Zampoli M., Elbert A., Burgel P., Carr S., Castaños C., Colombo C., Corvol H., Faro A., et al. (2021). Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. J Cyst Fibros, 20(1):25–30. https://doi.org/10.1016/j.jcf.2020.11.021
Betapudi B., Aleem A. & Kothadia J. (2022). Cystic Fibrosis And Liver Disease. NCBI StatPearls https://www.ncbi.nlm.nih.gov/books/NBK556086/
Bezzerri V., Lucca F., Volpi S. & Cipolli M. (2020). Does cystic fibrosis constitute an advantage in COVID-19 infection?. Ital J Pediatr, 46(1): 143. https://doi.org/10.1186/s13052-020-00909-1
CDC (2019). COVID-19 People with Certain Medical Conditions. Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
Cosgriff R., Ahern S., Bell S., Brownlee K., Burgel P., Byrnes C., Corvol H., Cheng S., Elbert A., et al. Global Registry Harmonization Group (2020). A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros, 19(3): 355–358. https://doi.org/10.1016/j.jcf.2020.04.012
Cystic Fibrosis Foundation (2024) The Clinical and Functional Translation of CFTR (CFTR2) (http://www.cftr2.org/mutations_history)
Doumit M., Chuang S., Middleton P., Selvadurai H., Sivam S., Ruseckaite R., Ahern S., Mallitt K. A., Pacey V., Gray K. & Jaffe A. (2023). Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic. Journal of Cystic Fibrosis, 22(3). https://doi.org/10.1016/j.jcf.2022.09.006
Driscoll S., Carroll W., Nichani S., Fishwick R., Bakewell K. & Gilchrist, F. (2022). COVID-19 infection and nocardiosis causing the death of an adolescent with cystic fibrosis. Pediatr Pulmonol, 10.1002/ppul.25954. https://doi.org/10.1002/ppul.25954
Endres T. & Konstan M. (2022). What Is Cystic Fibrosis? JAMA Jan 11;327(2):191. https://doi.org/10.1001/jama.2021.23280 PMID: 35015036
Fainardi V., Longo F., Chetta A., Esposito S., & Pisi G. (2020). Sars-CoV-2 infection in patients with cystic fibrosis. An overview. Acta Biomed, 91(3): e2020035. https://doi.org/10.23750/abm.v91i3.10391
Jackson C., Farzan M., Chen B. & Choe H. (2022). Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol, 23(1): 3–20. https://doi.org/10.1038/s41580-021-00418-x
Jaudszus A., Pavlova M., Rasche M., Baier M., Moeser A. & Lorenz, M. (2022). One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis. BMC pulmonary medicine, 22(1), 101. https://doi.org/10.1186/s12890-022-01900-8
Lotti V., Merigo F., Lagni A., Di Clemente A., Ligozzi M., Bernardi P., Rossini G., Concia E., Plebani R., Romano M., Sbarbati A., Sorio C., & Gibellini D. (2022). CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells. Cells, 11(8), 1347. https://doi.org/10.3390/cells11081347
Martínez-Hernández A, Mendoza-Caamal EC, Mendiola-Vidal NG, Barajas-Olmos F, Villafan-Bernal JR, et al. (2024). CFTR pathogenic variants spectrum in a cohort of Mexican patients with cystic fibrosis. Heliyon, 10(7):e28984. https://doi.org/10.1016/j.heliyon.2024.e28984
Mathew H., Choi M., Parkins M. & Fritzler M. (2021). Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med, 21(1): 173.https://doi.org/10.1186/s12890-021-01528-0
Moola F., Ross T., Buliung R., Neville A. & Hong S. (2024) We are Always in Self-Isolation”: Navigating COVID-19 as a Young Person in Canada with Cystic Fibrosis, Wellbeing, Space and Society (2024), doi: https://doi.org/10.1016/j.wss.2024.100202
Naehrlich L., Orenti A., Dunlevy F., Kasmi I., Harutyunyan S., Pfleger A., Keega S., Daneau G., Petrova G., Tješić-Drinković et al. (2021). Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. J Cyst Fibros, 20(4): 566–577. https://doi.org/10.1016/j.jcf.2021.03.017
Orozco L., Chávez M., Saldaña Y., Velázquez R., Carnevale A., González-del Ángel A. & Jiménez S. (2006). Fibrosis quística: la frontera del conocimiento molecular y sus aplicaciones clínicas. Rev Invest Clin, 58(2):139-152
O'Sullivan B. & Freedman S. (2009). Cystic fibrosis. Lancet, 373(9678): 1891–1904. https://doi.org/10.1016/S0140-6736(09)60327-5
Páez-Velásquez J., Romero-Uribe I., Castilla-Peón M., Lezana-Fernández J. & Chávez-López A. (2021). SARS-CoV-2 infection in a pediatric patient with cystic fibrosis. Bol Med Hosp Infant Mex, 78(1). https://doi.org/10.24875/bmhim.20000216
Pastrian-Soto G. (2020). Genetic and Molecular Basis of COVID-19 (SARS-CoV-2) Mechanisms of Pathogenesis and Imnune. Int. J. Odontostomat, 14(3), 331-337. http://dx.doi.org/10.4067/S0718-381X2020000300331
Peckham D., McDermott M., Savic S. & Mehta, A. (2020). COVID-19 meets cystic fibrosis: for better or worse? Genes Immun, 21(4): 260-262. https://doi.org/10.1038/s41435-020-0103-y
Ratchford T., Teckman J. & Patel D. (2018). Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Rev Gastroenterol Hepatol, 12(9):853–862. https://doi.org/10.1080/17474124.2018.1502663
Ruíz V., Hernández R. & de la Rosa G. (2018). Genética clínica. Manual Moderno, 2.ª ed., p. 582
Scotet V., L'Hostis C. & Férec C. (2020). The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (basel), 11(6): 589. https://doi.org/10.3390/genes11060589
Seyedi S., Sadeghi H., Kianifar H., Hamedi A. & Saeidinia A. (2022). COVID-19 infection in an infant with cystic fibrosis: A case report and possible therapeutic effect of hypertonic saline. Clin Case Rep, 10(4), e05782. https://doi.org/10.1002/ccr3.5782
Simonson J., Esposito C., Frantzen T., Henthorne K., Espinal A., Romano S., Ramdeo R., … & Wang, J. (2022). The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York. J Cyst Fibros, 21(3), e176–e183. https://doi.org/10.1016/j.jcf.2022.02.012
Singh V. & Schwarzenberg S. (2017). Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros, Suppl 2: S70–S78. https://doi.org/10.1016/j.jcf.2017.06.011
Stanton, B. A., Hampton, T. H., & Ashare, A. (2020). SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol. Lung Cell Mol Physiol, 319(3): L408–L415. https://doi.org/10.1152/ajplung.00225.2020
Tinajero Iriarte M., Lamshing Salinas P., Casaubon Garcín P. & Hernández Archundia E. (2016). Ileo meconial como primera manifestación de fibrosis quística. Anales med, 61(4): 305–309 https://www.medigraphic.com/pdfs/abc/bc-2016/bc164m.pdf
Turcios N. (2020). Cystic fibrosis lung disease: an overview. Respir Care, 65(2):233–251. https://doi.org/10.4187/respcare.06697
Yesudhas D., Srivastava A., & Gromiha M. (2021). COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection, 49(2): 199–213. https://doi.org/10.1007/s15010-020-01516-2
Yu E. & Sharma S. (2021). Cystic Fibrosis. NCBI StatPearls, NCBI https://www.ncbi.nlm.nih.gov/books/NBK493206/
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Revista Mesoamericana de Investigación
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
